Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03922724 · ClinicalTrials.gov registry record · Phase 2
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
A Phase 2 study of Immune System Diseases and Lymphoproliferative Disorders, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 330
- Enrollment target
- 2
- Study locations
NCT03922724 is a Phase 2 study of Immune System Diseases and Lymphoproliferative Disorders that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 330 participants, above the 134-participant average among 18 other Immune System Diseases trials with a reported enrollment target (146% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT03922724, a Phase 2 study of Immune System Diseases and Lymphoproliferative Disorders, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 330 participants
- Enrollment target
- 2
- Study locations
Study Summary
Background: Lymphoma is a type of blood cancer. Blood cell transplant can cure some people with lymphoma. Researchers want to see if they can limit the complications transplant can cause. Objective: To test if a stem cell transplant can cure or control lymphoma. Also to test if new ways of getting a recipient ready for a transplant may result in fewer problems and side effects. Eligibility: Recipients: People ages 12 and older with peripheral T cell lymphoma that does not respond to standard treatments Donors: Healthy people ages 18 and older whose relative has lymphoma Design: Participants will be screened with: Physical exam Blood and urine tests Bone marrow biopsy: A needle inserted into the participant s hip bone will remove marrow. Donors will also be screened with: X-rays Recipients will also be screened with: Lying in scanners that take pictures of the body Tumor sample Donors may donate blood. They will take daily shots for 5 7 days. They will have apheresis: A machine will take blood from one arm and take out their stem cells. The blood will be returned into the other arm. Recipients will be hospitalized at least 2 weeks before transplant. They will get a catheter: A plastic tube will be inserted into a vein in the neck or upper chest. They will get antibody therapy or chemotherapy. Recipients will get the transplant through their catheter. Recipients will stay in the hospital several weeks after transplant. They will get blood transfusions. They will take drugs including chemotherapy for about 2 months. Recipients will have visits 6, 12, 18, 24 months after transplant, then once a year for 5 years.
Conditions Studied
Interventions
- DRUG ATL-RIC
- DRUG mRIC
- PROCEDURE allo HCT
- DRUG RIC
- DRUG GVHD prophylaxis
Study Locations (2)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Minnesota
- National Marrow Donor Program - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2019-04-18 |
| Est. Completion | 2030-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03922724
The ClinicalTrials.gov registry entry for NCT03922724 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 134-participant average among 18 other Immune System Diseases trials with a reported enrollment target (146% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Immune System Diseases appearing as the primary indexed condition, and to 5 interventions - of which ATL-RIC is the first listed.
NCT03922724 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Maryland, Minnesota.
Frequently Asked Questions
What is clinical trial NCT03922724 about?
NCT03922724 is a clinical study titled "Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma". Background: Lymphoma is a type of blood cancer. Blood cell transplant can cure some people with lymphoma. Researchers want to see if they can limit the complications transplant can cause. Objective: To test if a stem cell transplant can cure or control lymphoma. Also to test if new ways of gettin...
What is the current status of trial NCT03922724?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 330 participants. The study started on 2019-04-18. Estimated completion is 2030-10-31.
What conditions does trial NCT03922724 study?
This clinical trial studies the following conditions: Immune System Diseases, Lymphoproliferative Disorders, Peripheral T-cell Lymphomas.
What interventions are being tested in trial NCT03922724?
The interventions under investigation include: ATL-RIC (DRUG), mRIC (DRUG), allo HCT (PROCEDURE), RIC (DRUG), GVHD prophylaxis (DRUG).
Who is sponsoring clinical trial NCT03922724?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03922724 being conducted?
This trial has 2 study locations across Maryland, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immune System Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
RECRUITING · Phase 2
-
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
RECRUITING · Phase 2
-
A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition
RECRUITING · Phase 2
-
A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy
ACTIVE NOT RECRUITING · Phase 2
-
Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation
ACTIVE NOT RECRUITING · Phase 2
-
Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.